Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00430781 · ClinicalTrials.gov registry record · Phase 2
Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer
A Phase 2 study of Metastatic Cervical Cancer and Neoplasms, Uterine Cervix, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 228
- Enrollment target
- 20
- Study locations
NCT00430781: Completed Phase 2 study of Metastatic Cervical Cancer and Neoplasms, Uterine Cervix, sponsored by GlaxoSmithKline.
NCT00430781 is a Phase 2 study of Metastatic Cervical Cancer and Neoplasms, Uterine Cervix that has completed, run by GlaxoSmithKline. The registered enrollment target is 228 participants, above the 75-participant average among 4 other Metastatic Cervical Cancer trials with a reported enrollment target (204% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00430781, a Phase 2 study of Metastatic Cervical Cancer and Neoplasms, Uterine Cervix, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 228 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone or pazopanib alone in subjects with metastatic cervical cancer
Primary Outcome
PFS is defined as the interval between the date of randomization and the date of disease progression or death due to any cause. The study was designed to test Combination vs. Lapatinib first. The result indicated that Combination would not show improvement over Lapatinib even if followed until the final analysis and the Combination arm was terminated. The monotherapy arms continued to the final analysis. Data shown here are from this interim analysis.
Conditions Studied
Interventions
- DRUG pazopanib (GW786034)
- DRUG lapatinib (GW572016)
Study Locations (20)
California
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Orange
- GSK Investigational Site - Stanford
Ohio
- GSK Investigational Site - Cleveland
- GSK Investigational Site - Columbus
Buenos Aires
- GSK Investigational Site - Capital Federal
- GSK Investigational Site - Ciudad Autonoma de Buenos Aires
Santa Fe Province
- GSK Investigational Site - Rosario
- GSK Investigational Site - Santa Fe
Other
- GSK Investigational Site - Quilmes
- GSK Investigational Site - Brussels
Georgia
- GSK Investigational Site - Augusta
Massachusetts
- GSK Investigational Site - Boston
New Mexico
- GSK Investigational Site - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2006-11 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
What the finished NCT00430781 record still lists
NCT00430781 is an interventional study that assigns participants to a tested intervention. The registered 228 participants enrollment target is mid-sized for trials with a published cap, above the 75-participant average among 4 other Metastatic Cervical Cancer trials with a reported enrollment target (204% higher).
The record links to 2 conditions, with Metastatic Cervical Cancer appearing as the primary indexed condition, and to 2 interventions - of which pazopanib (GW786034) is the first listed.
NCT00430781 names 20 study sites across 14 states, led by California, Ohio, Buenos Aires.
Frequently Asked Questions
What is clinical trial NCT00430781 about?
NCT00430781 is a clinical study titled "Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer". This study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone or pazopanib alone in subjects with metastatic cervical cancer
What is the current status of trial NCT00430781?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 228 participants. The study started on 2006-11. Estimated completion is 2011-07.
What conditions does trial NCT00430781 study?
This clinical trial studies the following conditions: Metastatic Cervical Cancer, Neoplasms, Uterine Cervix.
What interventions are being tested in trial NCT00430781?
The interventions under investigation include: pazopanib (GW786034) (DRUG), lapatinib (GW572016) (DRUG).
Who is sponsoring clinical trial NCT00430781?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00430781 being conducted?
This trial has 20 study locations across California, Georgia, Massachusetts, New Mexico, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
RECRUITING · Phase 2
-
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
RECRUITING · Phase 2
-
Dostarlimab and Cobolimab in Advanced Cervical Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Self-Hypnosis for the Enhanced Recovery After Surgery in Patients With Gynecologic Cancer
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05107908 · 228 participants · NA
Neuronal and Behavioral Effects of an Implicit Priming Approach to Improve Eating Behaviors in Obesity
- NCT05547698 · 228 participants · NA
A Study of Venoarterial ECMO vs Off-Pump Bilateral Orthotopic Lung Transplantation
- NCT05630963 · 228 participants
Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression
- NCT06073665 · 228 participants · Phase 4
Dosing of LT4 in Older Individuals
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia